C15-methoxyphenylated 18-deoxy-herbimycin A analogues, their in vitro anticancer activity and heat shock protein 90 binding affinity

Bioorg Med Chem Lett. 2016 Sep 1;26(17):4287-91. doi: 10.1016/j.bmcl.2016.07.040. Epub 2016 Jul 20.

Abstract

Benzoquinone ansamycins are important leads for the discovery of novel inhibitors of heat shock protein 90 (Hsp90), a promising target of cancer chemotherapeutics. Intrinsic hepatotoxicity caused by the benzoquinone moiety appeared to be a serious limitation to the development of these compounds. To solve this problem by rational structure optimization, a short series of C18-deoxy analogues of herbimycin A were designed based on putative interactions between the compound and the protein. Chemical synthesis of the target molecules were attempted by following the established synthetic route to the natural product, but resulted in the isolation of four serendipitous C15 phenylated final products. In vitro antiproliferative activity and Hsp90 binding affinity of the compounds were determined, suggesting the C18-oxygen of herbimycin A is removable and bulky lipophilic groups can be accommodated at C15 without loss of activity.

Keywords: Anticancer activity; C15-phenylated analogue; C18-deoxy analogue; Herbimycin A; Hsp90 inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / metabolism*
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • HSP90 Heat-Shock Proteins / metabolism*
  • Humans
  • Inhibitory Concentration 50
  • Models, Molecular
  • Protein Binding
  • Rifabutin / analogs & derivatives*
  • Rifabutin / chemical synthesis
  • Rifabutin / chemistry
  • Rifabutin / metabolism
  • Rifabutin / pharmacology

Substances

  • Antineoplastic Agents
  • HSP90 Heat-Shock Proteins
  • Rifabutin
  • herbimycin